At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised Double-Blinded Placebo-Controlled Trial to Assess the Efficacy and Safety of Scopolamine Compared to Placebo in Individuals With Bipolar Disorder Who Are Experiencing a Depressive Episode
In Brief
A Phase 2 clinical trial evaluating Placebo / Saline and Scopolamine for Bipolar Disorder Depression. Completed, enrolled 55 participants across 1 site.
Detailed Summary
This is a single-site, randomised, double-blind, placebo-controlled, parallel, phase IIb clinical trial. The primary objective of the SCOPE-BD study is to investigate the efficacy and safety of IV Scopolamine, compared to placebo, in reducing severity of depression in individuals with bipolar disorder who are experiencing a depressive episode of at least moderate severity
Study Details
Timeline
Interventions
The placebo group will receive a 100ml infusion of saline at 4 visits during the study
The treatment group will receive a 100ml infusion of Scopolamine ( dose 4μg/kg) at 4 visits during the study